Rhumbline Advisers Prelude Therapeutics Inc Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Rhumbline Advisers holds 12,004 shares of PRLD stock, worth $13,924. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,004
Previous 21,565
44.34%
Holding current value
$13,924
Previous $82,000
70.73%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding PRLD
# of Institutions
72Shares Held
35.7MCall Options Held
500Put Options Held
300-
Orbimed Advisors LLC San Diego, CA10.9MShares$12.7 Million0.53% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$11.7 Million0.22% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.77MShares$4.37 Million0.14% of portfolio
-
Boxer Capital, LLC San Diego, CA1.71MShares$1.98 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.1MShares$1.27 Million0.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $42.2M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...